MXPA05009526A - Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica. - Google Patents

Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.

Info

Publication number
MXPA05009526A
MXPA05009526A MXPA05009526A MXPA05009526A MXPA05009526A MX PA05009526 A MXPA05009526 A MX PA05009526A MX PA05009526 A MXPA05009526 A MX PA05009526A MX PA05009526 A MXPA05009526 A MX PA05009526A MX PA05009526 A MXPA05009526 A MX PA05009526A
Authority
MX
Mexico
Prior art keywords
cancer
viral infection
therapeutic treatment
myxoma virus
chronic viral
Prior art date
Application number
MXPA05009526A
Other languages
English (en)
Spanish (es)
Inventor
John C Bell
Original Assignee
Robarts Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robarts Res Inst filed Critical Robarts Res Inst
Publication of MXPA05009526A publication Critical patent/MXPA05009526A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MXPA05009526A 2003-03-07 2004-03-08 Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica. MXPA05009526A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45252103P 2003-03-07 2003-03-07
US45539303P 2003-03-18 2003-03-18
PCT/CA2004/000341 WO2004078206A1 (en) 2003-03-07 2004-03-08 Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection

Publications (1)

Publication Number Publication Date
MXPA05009526A true MXPA05009526A (es) 2005-12-15

Family

ID=32965588

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009526A MXPA05009526A (es) 2003-03-07 2004-03-08 Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.

Country Status (11)

Country Link
US (2) US7582614B2 (https=)
EP (1) EP1601376B1 (https=)
JP (2) JP4800924B2 (https=)
KR (1) KR101116858B1 (https=)
AU (1) AU2004216928C1 (https=)
CA (1) CA2517147C (https=)
IL (1) IL170601A (https=)
MX (1) MXPA05009526A (https=)
NZ (1) NZ541951A (https=)
RU (1) RU2362584C2 (https=)
WO (1) WO2004078206A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4800924B2 (ja) * 2003-03-07 2011-10-26 ロバーツ リサーチ インスティテュート 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
US20090035276A1 (en) * 2005-03-07 2009-02-05 Robarts Research Institute Use of a combination of myxoma virus and rapamycin for therapeutic treatment
WO2007143538A2 (en) * 2006-06-01 2007-12-13 Robarts Research Institute Pike-a enhances infection by myxoma virus
WO2007143548A2 (en) * 2006-06-01 2007-12-13 Robarts Research Institute Myxoma virus mutants for cancer treatment
WO2012171007A2 (en) * 2011-06-09 2012-12-13 University Of Florida Research Foundation, Inc. Methods for treating or preventing graft versus host disease
US20190350992A1 (en) * 2016-11-17 2019-11-21 Vcn Biosciences Sl Use of viral vectors in the treatment of retinoblastoma
EP3681998A1 (en) 2017-09-11 2020-07-22 IMBA-Institut für Molekulare Biotechnologie GmbH Tumor organoid model
WO2019177438A1 (ko) * 2018-03-16 2019-09-19 바이로큐어 주식회사 암 치료를 위한 레오바이러스 및 믹소마폭스 바이러스의 병용
RU2699754C1 (ru) * 2018-05-08 2019-09-09 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" Флуоресцирующая клеточная линия глиомы и способ её получения
US12128099B2 (en) 2018-05-25 2024-10-29 Bioventures, Llc Myxoma virus compositions and methods of use
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US20210169957A1 (en) * 2018-08-17 2021-06-10 Virocure, Inc. Combined use of squirrel poxvirus and myxoma poxvirus, for treating cancer
CA3112788A1 (en) * 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
US12428626B2 (en) 2018-11-20 2025-09-30 Bioventures, Llc Cells for the production of viruses and methods of using the same
US11591616B1 (en) 2019-04-22 2023-02-28 Colorado State University Research Foundation Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
ATE241994T1 (de) 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
EP1003894A2 (en) 1997-07-18 2000-05-31 Chiron Corporation Lentiviral vectors
CN101618049A (zh) 1997-10-09 2010-01-06 威尔斯塔特生物公司 使用病毒来治疗赘生物
ES2153284B1 (es) 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
IL145899A0 (en) 1999-04-15 2002-07-25 Pro Virus Inc Treatment of neoplasms with viruses
AU6175000A (en) * 1999-07-12 2001-01-30 Viron Therapeutics, Inc. Novel myxoma genes for immune modulation
JP4800924B2 (ja) * 2003-03-07 2011-10-26 ロバーツ リサーチ インスティテュート 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用
WO2007143545A2 (en) 2006-06-01 2007-12-13 Robarts Research Institute Tnf signaling in myxoma virus treatments

Also Published As

Publication number Publication date
RU2005131020A (ru) 2006-03-10
NZ541951A (en) 2008-03-28
JP2011157399A (ja) 2011-08-18
KR101116858B1 (ko) 2012-03-06
US20060263333A1 (en) 2006-11-23
IL170601A (en) 2010-11-30
JP4800924B2 (ja) 2011-10-26
US20090317362A1 (en) 2009-12-24
JP2006519789A (ja) 2006-08-31
US7582614B2 (en) 2009-09-01
AU2004216928B2 (en) 2007-03-08
AU2004216928C1 (en) 2007-03-08
HK1081099A1 (en) 2006-05-12
EP1601376B1 (en) 2012-05-30
EP1601376A1 (en) 2005-12-07
WO2004078206A1 (en) 2004-09-16
US8227440B2 (en) 2012-07-24
AU2004216928A1 (en) 2004-09-16
CA2517147C (en) 2011-06-14
RU2362584C2 (ru) 2009-07-27
KR20050111349A (ko) 2005-11-24
CA2517147A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
MXPA05009526A (es) Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.
Ip et al. Therapeutic vaccination against chronic hepatitis C virus infection
WO2010118367A3 (en) Antiviral pyrimidines
EA200601575A1 (ru) Казеиновые пептиды и их терапевтическое применение
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
AP2006003542A0 (en) Administration of TLR7 ligands and prodrugs for treatment of infection by hepatitis C virus.
WO2008096831A1 (ja) 癌の治療剤
TW200510343A (en) Substituted dihydroquinazolines
WO2008024843A3 (en) Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein
WO2006050489A3 (en) Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions
MXPA05008527A (es) Uso de artemisinina para tratar tumores inducidos por virus oncogenicos y para tratar infecciones virales.
WO2010093843A3 (en) Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
WO2006133099A3 (en) Sirna microbicides for preventing and treating viral diseases
WO2009061395A3 (en) Hcv combination therapies comprising vx-950, peg-ifn and ribavirin
MX2022001261A (es) Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.
UA96412C2 (ru) Применение комбинации вируса миксомы и рапамицина для лечения
TW200633995A (en) Andrographolide derivatives to treat viral infections
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
SE0300034D0 (sv) Use of strains of the parapox ovis virus for producting antiviral pharmaceuticals and anticancer pharmaceuticals
EA201101036A1 (ru) Применение хлорида аммония в терапии
WO2004052905A3 (en) Antiviral nucleoside derivatives
WO2007029041A3 (en) Interferon lambda therapy for treatment of respiratory diseases
WO2002026249A3 (en) Methods for inhibition of viral infection
WO2004018002A3 (en) Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
MX2022001271A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.

Legal Events

Date Code Title Description
FG Grant or registration